Blood Targets of Adjuvant Drugs Against COVID19

While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-k...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of blood medicine 2020-07, Vol.11, p.237-241
Hauptverfasser: Micco, Pierpaolo Di, Micco, Gianluca Di, Russo, Vincenzo, Poggiano, Maria Rita, Salzano, Ciro, Bosevski, Marijan, Imparato, Michele, Fontanella, Luca, Fontanella, Andrea
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle. Keywords: COVID19, flavonoid, heparin, ace-inhibitors, interleukin, angiotensin receptor blockers
ISSN:1179-2736
1179-2736
DOI:10.2147/JBM.S256121